Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 4/2014

01-12-2014 | Day-to-Day Practice

Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme

Authors: Joshua Mansour, Braxton Fields, Samuel Macomson, Olivier Rixe

Published in: Targeted Oncology | Issue 4/2014

Login to get access

Abstract

Glioblastoma multiforme (GBM) is the most aggressive subtype of malignant gliomas. Current standard treatment for GBM involves a combination of cytoreduction through surgical resection, followed by radiation with concomitant and adjuvant chemotherapy (temozolomide). The role of bevacizumab in the treatment of GBM continues to be a topic of ongoing research and debate. Despite aggressive treatment, these tumors remain undoubtedly fatal, especially in the elderly. Furthermore, tumors present in the pineal gland are extremely rare, accounting for only 0.1–0.4 % of all adult brain tumors, with this location adding to the complexity of treatment. We present a case of GBM, at the rare location of pineal gland, in an elderly patient who was refractory to initial standard of care treatment with radiation and concomitant and adjuvant temozolomide, but who developed a significant response to anti-angiogenic therapy using bevacizumab.
Literature
1.
Birbilis TA, Matis GK, Eleftheriadis SG et al (2010) Spinal metastasis of glioblastoma multiforme. Spine 35(7):264–269
2.
Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 1:97–109CrossRef
3.
Gasparetto EL, Warszawiak D, Adam GP et al (2003) Glioblastoma multiforme of the pineal region: case report. Neuro-Psiquitar 61(2B):468–472CrossRef
4.
Edwards MSB, Hudgins RJ, Wilson CB et al (1988) Pineal region tumors in children. J Neurosurg 68:689–697PubMedCrossRef
5.
Stupp R, Mason WP, van der Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–96PubMedCrossRef
6.
Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–66PubMedCrossRef
7.
Malstrom A, Gronberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractioned radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomized, phase 3 trial. Lancet Oncol 13(9):916–926CrossRef
8.
Gil-Gil MJ, Mesia C, Rey M, Bruna (2013) Bevacizumab for the treatment of glioblastoma. Clin Med Insights Onc 7:123–135CrossRef
9.
Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–9PubMedCrossRef
10.
11.
Henriksson R, Bottomley A, Mason W et al (2013) Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol 31 Suppl (abstr 2005)
12.
Taal W, Oosterkamp HM, Walenkamp A et al (2013). A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study. J Clin Oncol 31, 2013 Suppl (abstr 2001)
13.
Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-oncology working group. J Clin Oncol 28(11):1963–1972PubMedCrossRef
14.
Amini A, Schmidt RH, Salzman KL et al (2006) Glioblastoma multiforme of the pineal region. J Neurooncol 79:307–14PubMedCrossRef
15.
Chamberlain MC, Glantz MJ, Chamlmers L et al (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82:81–83PubMedCrossRef
16.
Brandes A, Tosoni A, Spagnolli F et al (2007) Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology. Neuro-Oncology 10:361–367CrossRef
17.
18.
Brandsma D, van den Bent MJ (2009) Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22(6):633–638PubMedCrossRef
19.
Wick W, Wick A, Weiler M, Weller M (2011) Patterns of progression in malignant glioma following anti-VEGF therapy; perceptions and evidence. Curr Neurol Neurosci Rep 11(3):305–312PubMedCrossRef
20.
Levin VA, Bidaut L, Hou P et al (2011) Randomized double-blind placebo-controlled trial of bevaczumab for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79(5):1487–95PubMedCentralPubMedCrossRef
21.
Johnson DR, Leeper HE, Uhm JH (2013) Glioblastoma survival in the Unites States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis. Cancer. doi:10.​1002/​cncr.​28259
Metadata
Title
Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme
Authors
Joshua Mansour
Braxton Fields
Samuel Macomson
Olivier Rixe
Publication date
01-12-2014
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 4/2014
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-014-0327-8

Other articles of this Issue 4/2014

Targeted Oncology 4/2014 Go to the issue

Original Research

Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort

Original Research

Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment

Original Research

Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer

Review

Curcumin and lung cancer—a review

Original Research

Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT

Original Research

Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits